P21

P21, also indexed as P021, is a CNTF-derived neurotrophic peptide mimetic reported as Ac-DGGLAG-NH2 in foundational literature. Its evidence base is broader than many research peptides but still almost entirely preclinical. Initial mouse work found improved learning and memory measures, increased dentate gyrus neurogenesis, and maturation of newly born neurons. Follow-up studies extended the signal into aged rats and 3xTg-AD mouse models, where oral P021 was associated with improved cognition-related measures, synaptic and dendritic marker preservation, neurogenesis support, and reduced Alzheimer-like pathology markers in some protocols. P21 should be framed as preclinical neurotrophic and neuroregeneration research, not as a human cognitive or Alzheimer therapy.

Neurogenesis and Synaptic Plasticity

P21/P021 enhanced learning and memory measures in adult mice and increased dentate gyrus neurogenesis and maturation of newly born neurons ^[1].

Aging and Alzheimer-Model Research

Chronic oral P021 reduced age-associated learning and memory decline in aged rats and improved synaptic, dendritic, and cognitive-task markers in 3xTg-AD mouse models ^[2][3][4].

Evidence Boundary

These findings are preclinical and should not be presented as evidence that P21 prevents or treats Alzheimer disease in humans ^[3][4].

Rodent Evidence Limits

P21/P021 data are predominantly rodent data; they do not establish human safety, dosing, or therapeutic efficacy ^[1][2][3].

Clinical Translation Gap

The compound was designed to improve drug-like properties compared with larger neurotrophic factors, but design rationale is not a substitute for clinical toxicology ^[4].